Grants and Contributions:

Title:

Development of recombinant multispecific antibodies in immuno-oncology simultaneously targeting tumor-associated antigens, tumor invasion and immune system modulation

Agreement Number:

993841

Agreement Value:

$490,750.00

Agreement Date:

Aug 5, 2022 - Jan 31, 2024

Description:

The main objective of the project is to develop at least one bispecific or multispecific therapeutic antibody in pulmonary immuno-oncology. To this end, the company will improve its platform to accelerate the therapeutic antibody discovery process through the implementation of new technologies, automation and high throughput processing of the experimental data collected. This platform will be able to efficiently generate multispecific antibodies with demonstrated therapeutic efficacy.

Organization:

National Research Council Canada

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:

Sherbrooke, Quebec, CA J1E 0M8

Reference Number:

172-2022-2023-Q2-993841

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

805852886

Recipient Type:

For-profit organization

Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 47 days.

Amendment Date

Oct 17, 2023

Recipient's Operating Name:

Immune Biosolutions

Recipient's Legal Name:

Immune Biosolutions inc.

Federal Riding Name:

Sherbrooke

Federal Riding Number:

24073

Program:

Industrial Research Assistance Program – Contributions to Firms

Program Purpose:

Coverage:

IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.

NAICS Code:

54171

Amendments:

See Amendments